The definition of labels is well defined and ususally well known; "labeling" not so well. Differing requirements for different applications can be confusing and are the subject of this webinar.
Why Should You Attend
Labels and Labeling. Label for various typeds of products or types of submissions. All can be confusing. The FDA looks very carefully at labeling during both device submissions reviews as well as CGMP compliance audits. Problems in label composition, application, and also in their control, handling, issuance, and reconciliation can get a company quickly in trouble. Review the basics of labels / labeling, and see the various areas of application in this webinar, including some little known or controlled areas which are subject to regulatory scruinty by both the FDA, and even a competitor trying to "level the playing field" with their competition.
FDA medical device labeling requirements are found in several CFRs, i.e.,
- General Device Labeling - 21 CFR Part 801;
- Use of Symbols - 21 CFR Part 801.15;
- In Vitro Diagnostic Products - 21 CFR Part 809;
- Investigational Device Exemptions - 21 CFR Part 812;
- Unique Device Identification - 21CFR Part 830;
- Good Manufacturing Practices - 21 CFR Part 820;
- General Electronic Products - 21 CFR Part 1010.
Add to this the UDI / GUDID requirements, and also court decisions that marketing is labeling. Confusing? This webinar will break these requirements down into the basics and examine means to comply with each category of requirement.
- Label vs. Labeling
- Basic CGMPs and Labeling
- Submission categories of labeling.
- Specific required controls.
- On product, on carton, on shipper labels; IFUs
- Shipper labels - their differences
- UDI (and GUDID)
- Product category differentiation
- Marketing and "labeling".
Who Will Benefit
This webinar will provide valuable assistance to all regulated medical device companies that need to review and ensure their labels / labeling meet current US FDA requirements. The employees who will benefit include:
- Senior management
- Regulatory Affairs
- Quality Assurance
- Sales and Marketing
Faculty John E. Lincoln
Principal of J. E. Lincoln and Associates LLC
John E. Lincoln, is Principal of J. E. Lincoln and Associates LLC, a consulting company with over 36 years experience in U.S. FDA-regulated industries, 22 of which are as an independent consultant. John has worked with companies from start-up to Fortune 100, in the U.S., Mexico, Canada, France, Germany, Sweden, China and Taiwan. He specializes in quality assurance, regulatory affairs, QMS problem remediation and FDA responses, new / changed product 510(k)s, process / product / equipment QMS and software validations, ISO 14971 product risk management files / reports, Design Control / Design History Files, Technical Files, CAPA systems and analysis.